article · Science Journal of University of Zakho
This study investigates the co-infection of HCV and its risk factors amongst HIV-positive patients in Ilorin, Kwara State, Nigeria. Consenting HIV-positive individuals (n=188) from the HAART clinic at Sobi Specialist Hospital participated. Data was collected via structured questionnaire while Anti-HCV antibodies were determined via a 3rd-generation ELISA kit (Diagnostic Automation Inc., USA). SPSS version 21 and R-Studio 4.5.1 were used for the data analysis and multivariable logistic regression model analysis after adjusting for confounding variables at p≤ 0.05 and 95%CI for statistical significance. Participants average was 31.47±7.79 years comprising 41.5% and 58.5%. HCV seropositivity was 8.5%. Significant association with HCV infection included age (p < 0.001-AOR:4.28-CI:1.82-10.13) and marital status (p=0.026-AOR:2.65-CI:1.14-6.18). Clinically, history of jaundice (p=0.028- AOR:3.45-CI:1.09-10.84) and recent blood transfusion (p = 0.030) were also significant risk factors; whereas, surgery, tattooing, homosexual practices, and injection drug use were not. HCV-positivity was common among participants with low CD4 counts (<500 cells/mm³) at p=0.94). Similarly, anti-retroviral therapy (ART) duration showed no significant association to HCV status. This study confirms the occurrence of HIV/HCV co-infection in Ilorin, emphasizing the roles of specific sociodemographic and clinical variables. Routine HCV screening within HIV care is recommended to enable early diagnosis, optimize management and improve patient outcomes.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.25271/sjuoz.2026.14.2.1831
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.